GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OrbusNeich Medical Group Holdings Ltd (HKSE:06929) » Definitions » Net Income

OrbusNeich Medical Group Holdings (HKSE:06929) Net Income : HK$309 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is OrbusNeich Medical Group Holdings Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. OrbusNeich Medical Group Holdings's Net Income for the six months ended in Jun. 2024 was HK$147 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jun. 2024 was HK$309 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. OrbusNeich Medical Group Holdings's Earnings per Share (Diluted) for the six months ended in Jun. 2024 was HK$0.18.


OrbusNeich Medical Group Holdings Net Income Historical Data

The historical data trend for OrbusNeich Medical Group Holdings's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OrbusNeich Medical Group Holdings Net Income Chart

OrbusNeich Medical Group Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income
Get a 7-Day Free Trial 54.81 -34.66 143.96 352.01 308.74

OrbusNeich Medical Group Holdings Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only 81.39 197.26 155.34 147.05 162.38

OrbusNeich Medical Group Holdings Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

OrbusNeich Medical Group Holdings's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=387.585+-35.574+0+5.6843418860808E-14
=352

OrbusNeich Medical Group Holdings's Net Income for the quarter that ended in Jun. 2024 is calculated as

Net Income(Q: Jun. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=166.236+-18.838+0+-0.351
=147

Net Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$309 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OrbusNeich Medical Group Holdings  (HKSE:06929) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

OrbusNeich Medical Group Holdings's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


OrbusNeich Medical Group Holdings Net Income Related Terms

Thank you for viewing the detailed overview of OrbusNeich Medical Group Holdings's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


OrbusNeich Medical Group Holdings Business Description

Traded in Other Exchanges
Address
3rd Floor, Building 20E, Units 303 and 305, Hong Kong Science Park, Shatin New Town, Hong Kong, HKG
OrbusNeich Medical Group Holdings Ltd is a China-based medical device maker of endovascular interventional instruments with majority reach. It launched its first research base in 2001 and was listed on the Hong Kong Exchange in 2022. As of 2023, OrbusNeich's majority revenue segment by geography is Japan with 24.7% of total revenue followed by Europe, the Middle East, and Africa, with 23.6% of total revenue. The Asia-Pacific region and the United States make up the balance. Its product segment is coronary interventional medical devices, such as scoring balloons, non-compliant balloons, or stents, together representing 82.7% of its total revenue.
Executives
Harmony Tree Limited 2101 Beneficial owner
Shenzhen Capital Group Co., Ltd. 2201 Interest of corporation controlled by you
Suzhou Red Earth Yeju Investment Ltd. 2101 Beneficial owner
Chien David 2201 Interest of corporation controlled by you
Lau Kwai Ching Denise 2201 Interest of corporation controlled by you
Shen Chuang Tou Zhi Zao Ye Zhuan Xing Sheng Ji Xin Cai Liao Ji Jin You Xian He Huo 2201 Interest of corporation controlled by you
Shen Chuang Tou Hong Tu Si Mu Gu Quan Tou Zi Ji Jin Guan Li Shen Zhen You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Hong Tu Ye Ju Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you

OrbusNeich Medical Group Holdings Headlines

No Headlines